Celldex Therapeutics, Inc.

As of June 30, 2026, Celldex Therapeutics, Inc. carries a market capitalization of 2.57B, placing it among publicly traded companies globally. Its enterprise value stands at 1.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Celldex Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Celldex Therapeutics, Inc. has 78.50M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 16,432.68, and the price-to-book ratio stands at 4.11.

These figures are as of June 30, 2026. The EV/Sales ratio of 14,095.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.95B versus a market cap of 2.57B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Celldex Therapeutics, Inc. maintains a current ratio of 11.82, meaning it holds 11.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Celldex Therapeutics, Inc. posted a negative return on equity (ROE) of -43.88, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -40.76, reflecting losses generated across the asset base. The company generates approximately 709.22 in revenue per employee across its workforce of 195.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Celldex Therapeutics, Inc.'s stock has gained approximately 11.61% over the past 52 weeks. The 50-day moving average sits at 30.92, while the 200-day moving average is 28.25.

Over the twelve months ended June 30, 2026, Celldex Therapeutics, Inc. generated 138,297.40 in revenue and converted that into -263.07M in net income, yielding earnings per share of -3.79. EBITDA reached -282.22M, while operating income came in at -285.20M.

As of June 30, 2026, Celldex Therapeutics, Inc. holds 628.10M in cash and equivalents against 4.29M in total debt, resulting in a net debt position of -41.54M. Total book value stands at 625.46M, with working capital of 580.85M providing operational flexibility.

Celldex Therapeutics, Inc. produced -206.19M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -5.72M in capital expenditures, free cash flow totaled -211.91M - equivalent to -3.06 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -206,220.25 and net profit margin of -190,220.89 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.32: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -11.13, meaning Celldex Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Celldex Therapeutics, Inc.'s most recent stock split took place on February 11, 2019 with a 15:1 split ratio.

As of June 30, 2026, Celldex Therapeutics, Inc. has an Altman Z-Score of 22.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.